Document is current
Any future updates will be listed below
-
Authors
Rizvi-Toner, Amna https://orcid.org/0009-0005-5407-9070
Coe, Antoinette B. https://orcid.org/0000-0002-5723-0443
Friese, Christopher R. https://orcid.org/0000-0002-2281-2056
Manojlovich, Milisa https://orcid.org/0000-0002-6101-5535
Wallner, Lauren P. https://orcid.org/0000-0002-1279-8617
Farris, Karen B. https://orcid.org/0000-0002-5636-3009
-
Funding
Funding for this research was provided by:
National Cancer Institute (T32- CA- 236621)
American Foundation for Pharmaceutical Education
- License Information
-
More Information
Article History
Received: 16 September 2025
Accepted: 3 February 2026
First Online: 13 February 2026
Declarations
:
: This study is approved by the Institutional Review Board of University of Michigan Medical School (IRBMED) and was performed in accordance with the 1964 Declaration of Helsinki and its later amendments.
: Written informed consent was obtained from all individual participants included in this study.
: KBF had funding from AstraZeneca to understand a model of collaboration between primary care and oncology pharmacists in managing patients with new oral anticancer agents. The funded study did not have any relationship with the current study.
